RJA
TVRD

Raymond James & Associates’s Tvardi Therapeutics TVRD Stock Holding History

Raymond James & Associates’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-285
Closed -$125K – 4300
2021
Q4 		$125K Hold
285
– – ﹤0.01% 3825
2021
Q3 		$159K Sell
285
-78
-21% -$39.1K ﹤0.01% 3723
2021
Q2 		$186K Sell
363
-27
-7% -$17.1K ﹤0.01% 3701
2021
Q1 		$305K Buy
390
+7
+2% +$4.79K ﹤0.01% 3350
2020
Q4 		$209K Buy
383
+4
+1% +$2.1K ﹤0.01% 3373
2020
Q3 		$174K Sell
379
-23
-6% -$13.4K ﹤0.01% 3264
2020
Q2 		$247K Sell
402
-53
-12% -$29.3K ﹤0.01% 3023
2020
Q1 		$216K Sell
455
-139
-23% -$75.5K ﹤0.01% 2988
2019
Q4 		$345K Sell
594
-53
-8% -$37.2K ﹤0.01% 2993
2019
Q3 		$426K Sell
647
-36
-5% -$29.9K ﹤0.01% 2763
2019
Q2 		$529K Sell
683
-127
-16% -$89.2K ﹤0.01% 2620
2019
Q1 		$572K Buy
810
+500
+161% +$299K ﹤0.01% 2564
2018
Q4 		$145K Sell
310
-64
-17% -$41.3K ﹤0.01% 3231
2018
Q3 		$323K Buy
374
+11
+3% +$7.94K ﹤0.01% 2977
2018
Q2 		$250K Buy
+363
New +$185K ﹤0.01% 3127
2018
Q1 		– Sell
-453
Closed -$199K – 3608
2017
Q4 		$199K Buy
+453
New +$207K ﹤0.01% 3066
2017
Q3 		– Sell
-312
Closed -$173K – 3503
2017
Q2 		$173K Buy
+312
New +$198K ﹤0.01% 3025

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Raymond James & Associates's TVRD Position: Q1 2022 in Review

Raymond James & Associates sold out of Tvardi Therapeutics (TVRD) in Q1 2022, closing a stake of 285 shares — an estimated $125K sold.

Raymond James & Associates first reported a position in TVRD in Q2 2017 and held it in 17 quarters. The position peaked at $572K in Q1 2019. 182 funds tracked by Wall St. Rank hold TVRD as of Q1 2022.

  • Raymond James & Associates reported no remaining Tvardi Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Raymond James & Associates sold 285 Tvardi Therapeutics shares in Q1 2022, an estimated $125K.
  • Raymond James & Associates first reported a position in Tvardi Therapeutics in Q2 2017 and held it in 17 quarters.
  • Raymond James & Associates's Tvardi Therapeutics position peaked at $572K in Q1 2019.
  • 182 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2022.

Based on Raymond James & Associates's 13F filing for Q1 2022, filed 11 May 2022.